George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term efficacy and safety data from a 52-week open-label extension of its pivotal Phase 3 study in treatment-naïve patients with hypertension. In this 52-week follow-up period of 50 subjects, treatment with GMRx2 (US tradename WIDAPLIKTM), demonstrated sustained blood pressure (BP) control out to one year, with good tolerability and low treatment discontinuation.

The data were presented in a moderated poster session, “Change is in the Air! New Discoveries in Hypertension Treatment”, at the American Heart Association’s (AHA) Scientific Sessions 2025, taking place in New Orleans, USA.

WIDAPLIK is an innovative single pill combination of three medicines: telmisartan, amlodipine and indapamide, for the treatment of hypertension, developed in three doses, including two doses that are lower than those currently available in single pill combinations. By leveraging a multi-mechanism approach and lower doses, WIDAPLIK is formulated to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the known safety profiles of existing antihypertensive medicines.

To evaluate the long-term efficacy and safety of WIDAPLIK-based treatment when used in usual clinical care, 50 participants from Sri Lanka and Nigeria sites of the placebo-controlled GMRx2_PCT study (NCT04518306), were enrolled into an open-label extension phase with GMRx2 treatment to one year. A total of 48 (96%) participants completed the study.

Mean home and in-clinic blood pressures following 4-weeks of the core double blind study period entering into the open-label extension were 121/78 mmHg and 126/79 mmHg, respectively.Following 52-week open label dosing, mean home BP was maintained at 120/78 mmHg, as was in-clinic BP of 122/77 mmHg.Home BP control (